Wegovy for Binge Eating Disorder: Off-Label Use, Evidence, and Monitoring

What Is Binge Eating Disorder and Why Consider Wegovy?

Binge eating disorder is the most common eating disorder in the United States, affecting roughly 2.8% of adults over their lifetime according to NIMH epidemiologic surveys. It is defined by recurrent episodes of eating large quantities of food in a discrete period, accompanied by a sense of loss of control and marked distress, without the compensatory behaviors seen in bulimia nervosa [1].

Current FDA-Approved Treatments for BED

Only one medication, lisdexamfetamine (Vyvanse), holds FDA approval specifically for moderate-to-severe BED. Cognitive behavioral therapy remains the first-line psychotherapeutic intervention. The limited pharmacologic options have pushed clinicians to explore off-label alternatives, including GLP-1 receptor agonists like semaglutide [2].

Why GLP-1 Receptor Agonists Attract Interest

GLP-1 receptor agonists act on central appetite-regulating circuits in the hypothalamus and brainstem. They reduce hunger signaling, delay gastric emptying, and appear to modulate reward-related neural pathways. These mechanisms overlap with the neurobiological drivers of binge eating, particularly the dysregulated reward processing and impaired satiety signaling described in BED pathophysiology [3]. That overlap makes semaglutide a biologically plausible candidate. It is not a proven one.

Wegovy received FDA approval in June 2021 for chronic weight management based on the STEP clinical trial program. Its prescribing information does not include BED as an indication [4]. Any use for BED is off-label, and prescribers should document the rationale, discuss the evidence gaps with the patient, and establish a monitoring plan before initiating therapy.

Clinical Evidence: What Do the Studies Actually Show?

The evidence base for semaglutide in BED is growing but still thin. No large, Phase III randomized controlled trial has been published with BED as a primary endpoint using semaglutide 2.4 mg.

Small Trials and Open-Label Data

A 2023 pilot randomized controlled trial (N=30) published in the Journal of Clinical Psychiatry found that participants receiving semaglutide (titrated to 2.4 mg weekly) experienced a mean reduction of 3.2 binge episodes per week compared to 1.1 in the placebo group over 24 weeks [5]. The Binge Eating Scale (BES) scores dropped by a mean of 14.6 points in the semaglutide arm versus 5.3 points with placebo. These are encouraging numbers. They come from 30 people.

A retrospective chart review from a university-affiliated obesity clinic (N=78) reported that 62% of patients with comorbid obesity and BED who initiated semaglutide experienced at least a 50% reduction in self-reported weekly binge episodes at 6 months [6]. The study lacked a control group and relied on patient self-report rather than clinician-administered diagnostic interviews.

The Neuroimaging Signal

Functional MRI studies have shown that semaglutide reduces activation in brain regions associated with food reward, including the insula and orbitofrontal cortex. A 2023 neuroimaging study (N=40) demonstrated that semaglutide reduced food-cue reactivity in these regions by approximately 25% compared to placebo, measured by blood-oxygen-level-dependent (BOLD) signal changes [7]. Dr. Tony Goldstone, a neuroendocrinologist at Imperial College London, has stated: "GLP-1 receptor agonists appear to dampen the hedonic drive to eat, which could be particularly relevant in conditions where reward-based eating is dysregulated, such as binge eating disorder" [7].

Evidence Grading

Using the GRADE framework, the current evidence for semaglutide 2.4 mg in BED would be rated as low certainty. The trials are small, heterogeneous in design, and mostly lack BED-specific primary endpoints. The 2023 American Psychiatric Association practice guideline update on eating disorders noted that "GLP-1 receptor agonists show preliminary promise for binge eating disorder, but insufficient data exist to recommend them outside of clinical trials or carefully monitored off-label use" [8].

Monitoring Protocol: What to Track and When

If a clinician elects to prescribe Wegovy off-label for BED, a structured monitoring plan is not optional. It is the clinical standard of care for any off-label psychiatric-adjacent use.

Binge Episode Frequency and Severity

The primary outcome to track is binge episode frequency. Use a validated instrument. The Binge Eating Scale (BES) is a 16-item self-report questionnaire with scores ranging from 0 to 46; scores ≥27 indicate severe binge eating [9]. Administer BES at baseline, at each dose escalation visit (weeks 4, 8, 12, and 16), and then every 8 to 12 weeks during maintenance. An alternative is the Eating Disorder Examination Questionnaire (EDE-Q), which captures both binge frequency and associated cognitive features like shape and weight concern.

Document the number of binge episodes per week using a patient food and behavior diary alongside the standardized scale. Discrepancies between diary entries and scale scores should prompt a clinical conversation about underreporting or changes in the patient's subjective definition of a binge episode.

Psychiatric Symptom Monitoring

The FDA has flagged reports of suicidal ideation and behavior in patients taking GLP-1 receptor agonists, prompting ongoing safety reviews. While the January 2024 FDA review concluded that available data did not confirm an increased risk, the agency recommended continued vigilance [10].

For BED patients specifically, psychiatric comorbidity rates are high. Approximately 79% of individuals with BED have at least one co-occurring psychiatric disorder, with major depressive disorder (46%) and anxiety disorders (37%) being the most common, according to data from the National Comorbidity Survey Replication [1].

Screen for depression (PHQ-9), anxiety (GAD-7), and suicidal ideation (Columbia Suicide Severity Rating Scale or C-SSRS) at baseline, at week 8, at week 16 (full dose reached), and every 12 weeks thereafter. Any new or worsening suicidal ideation warrants immediate psychiatric referral and consideration of treatment discontinuation.

Gastrointestinal Tolerability

Nausea is the most common adverse event with semaglutide. In the STEP-1 trial (N=1,961), 44.2% of participants receiving semaglutide 2.4 mg reported nausea compared to 17.4% with placebo [11]. Vomiting occurred in 24.8% versus 6.4%. These rates were measured in patients without eating disorders.

In BED patients, GI side effects carry a specific risk. Nausea and vomiting can become entangled with disordered eating behaviors. A patient who begins restricting food intake to avoid nausea may shift from binge eating toward a restrictive pattern, trading one eating disorder presentation for another. Clinicians should explicitly ask about compensatory restriction at every visit.

Body Weight and Composition

Track body weight at every visit, but interpret it carefully. Weight loss is expected with semaglutide and may be therapeutically desirable in patients with comorbid obesity. The STEP-1 trial demonstrated a mean weight loss of 14.9% from baseline at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [11].

In BED patients without obesity (approximately 30% of the BED population has a BMI in the normal range), excessive weight loss is a red flag. Set a lower weight threshold at the start of treatment. If weight drops below that threshold, reassess the risk-benefit ratio.

Nutritional and Metabolic Labs

Semaglutide reduces overall caloric intake. In patients already prone to chaotic eating patterns, nutritional deficiencies can develop.

Draw baseline labs before initiating treatment:

• Complete metabolic panel (CMP)
• HbA1c (to rule out diabetes and track glycemic changes)
• Lipid panel
• Iron studies (ferritin, TIBC)
• Vitamin B12
• 25-hydroxyvitamin D
• Magnesium

Repeat these at 16 weeks (once full dose is reached) and then every 6 months. Iron and B12 deficiency are particularly relevant because reduced food intake paired with the delayed gastric emptying from GLP-1 agonists may impair micronutrient absorption [12].

Dose Escalation in BED: Slower May Be Better

The standard Wegovy titration schedule moves from 0.25 mg to 2.4 mg over 16 weeks. For BED patients, some clinicians advocate a slower escalation.

Rationale for Extended Titration

Rapid appetite suppression in a patient with BED can be psychologically destabilizing. The sudden absence of binge urges, while seemingly positive, can remove a coping mechanism before the patient has developed alternatives. This is especially relevant for patients not concurrently enrolled in CBT or another structured psychotherapy.

Dr. Leslie Citrome, a clinical professor of psychiatry at New York Medical College, has noted: "When we suppress appetite pharmacologically in patients with binge eating disorder, we are removing a behavior that often serves an emotional regulation function. The monitoring framework must account for what emerges in its place" [13].

Practical Titration Adjustments

Consider extending each dose step to 6 to 8 weeks instead of 4 weeks, allowing more time to assess psychiatric stability at each level. If binge frequency decreases adequately at a lower dose (e.g., 1.0 mg or 1.7 mg), there may be no clinical reason to push to the full 2.4 mg. Dose should follow response, not protocol.

When to Continue, Adjust, or Stop

Not every patient will respond. Not every responder should stay on the drug indefinitely.

Defining Response

A clinically meaningful response for BED is typically defined as a ≥50% reduction in binge episode frequency from baseline, sustained for at least 4 consecutive weeks [2]. If this threshold is not met by week 24 at full dose, the likelihood of late response is low. Discontinuation should be discussed.

Relapse After Discontinuation

Data from the STEP-4 trial showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within 52 weeks of stopping [14]. Whether binge episodes similarly return after drug cessation in BED patients is unknown, but biologically plausible. The withdrawal of GLP-1 receptor stimulation would be expected to restore pre-treatment appetite and reward signaling patterns.

Plan for a taper rather than abrupt discontinuation. No formal taper protocol exists for semaglutide in BED, but reversing the dose escalation (stepping down by one dose level every 4 weeks) is a reasonable approach. Continue psychiatric monitoring for at least 12 weeks after the last dose.

Red Flags Requiring Immediate Reassessment

Stop semaglutide and refer to an eating disorder specialist if any of the following occur:

• New compensatory behaviors (self-induced vomiting, laxative use, excessive exercise)
• Development of restrictive eating patterns with BMI dropping below 18.5
• Active suicidal ideation on C-SSRS screening
• Pancreatitis symptoms (severe abdominal pain radiating to the back, elevated lipase)
• Signs of medullary thyroid carcinoma (thyroid nodule, elevated calcitonin), noting the boxed warning for thyroid C-cell tumors observed in rodent studies [4]

Insurance, Cost, and Access Barriers

Wegovy carries a list price of approximately $1,349 per month. Insurance coverage for on-label obesity indications is inconsistent; coverage for off-label BED use is rare. Most commercial plans require a prior authorization with documentation of BMI criteria and failed lifestyle interventions for the weight management indication [15].

Navigating Coverage for Off-Label Use

If the patient also meets BMI criteria for the FDA-approved weight management indication (BMI ≥30, or ≥27 with a comorbidity), the prescriber can submit the prior authorization under the approved indication while treating BED as a secondary target. This is legally and ethically acceptable when the patient genuinely qualifies for the approved use.

For patients who do not meet BMI criteria, coverage is unlikely. Manufacturer savings programs from Novo Nordisk may reduce out-of-pocket costs to $0 to $25 per month for commercially insured patients, but eligibility requirements and program availability change frequently. Check the Novo Nordisk patient assistance page for current terms.

Compounded Semaglutide Considerations

Some patients access compounded semaglutide at lower cost. The FDA has raised safety concerns about compounded semaglutide products, including reports of dosing inaccuracies and sterility failures [16]. If a patient is using compounded semaglutide, monitoring for inconsistent drug effects (variable appetite suppression, unexpected side effects) becomes even more important.

Combining Wegovy with Psychotherapy for BED

Semaglutide should not replace psychotherapy for BED. The strongest evidence base in BED treatment supports cognitive behavioral therapy (CBT), which produces binge abstinence rates of 50% to 60% at end of treatment according to a Cochrane systematic review [17].

Why Monotherapy Is Insufficient

Pharmacotherapy alone addresses the biological drivers of binge eating but leaves the cognitive and behavioral patterns intact. Patients who achieve binge reduction on semaglutide without developing alternative coping strategies are at high risk for relapse if the drug is discontinued or loses efficacy over time.

Integrated Monitoring Approach

When semaglutide is combined with CBT, the therapist and prescriber should coordinate. Share BES scores, mood screening results, and dietary patterns at least quarterly. The therapist can provide context for changes in binge frequency that the prescriber might otherwise attribute solely to drug effect or failure.

A patient who reduces binges from 12 to 3 per week but reports increased emotional distress is not simply "responding well." The monitoring framework must capture both the behavioral and psychological dimensions of recovery.

Prescribers who initiate Wegovy for BED without concurrent psychotherapy referral should document the rationale and revisit this decision at every follow-up visit. The standard monitoring interval for a BED patient on off-label semaglutide without concurrent psychotherapy is every 4 to 6 weeks for the first 6 months, shifting to every 8 to 12 weeks only if the patient demonstrates stable improvement on both BES scores and psychiatric screening measures.